Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597605 | 0.70 | ADRA2A (0.42) | — | |
| SCHEMBL21597512 | 0.68 | RAD52 (0.42) | — | |
| SCHEMBL1145384 | 0.66 | — | — | |
| SCHEMBL21605073 | 0.65 | — | — | |
| SCHEMBL31734266 | 0.65 | — | — | |
| SCHEMBL10138644 | 0.65 | — | — | |
| SCHEMBL21211975 | 0.65 | — | — | |
| SCHEMBL21597543 | 0.65 | CCNK (0.39) | — | |
| Hydrochloric Acid SCHEMBL23754450 | 0.63 | ATM (0.38) | GRM4PIK3CAPRMT5WDR77ATM | |
| Hydrochloric Acid SCHEMBL21598454 | 0.63 | ATM (0.38) | GRM4PIK3CAPRMT5WDR77ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | claimed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | GRM4 1518/4885PIK3CA 1502/4885PRMT5 1062/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | GRM4 2982/4885PIK3CA 2565/4885PRMT5 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.